Jefferies raises Amgen stock price target on drug trial success By Investing.com
Jefferies raises Amgen stock price target on drug trial success By Investing.com Investing.com South Africa
Covered in this story
What has happened since
- Amgen is up 8.2% since this was published, 31 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 8 Oct 2026.
Summary aggregated from Investing.com South Africa's public RSS feed. The full reporting belongs to Investing.com South Africa — please read it on their site.